Arcellx, Inc.

NasdaqGS:ACLX Stock Report

Market Cap: US$6.7b

Arcellx Valuation

Is ACLX undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Below Future Cash Flow Value

  • Significantly Below Future Cash Flow Value

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Analyst Forecast

Share Price vs Future Cash Flow Value

What is the Fair Price of ACLX when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Ultimate guide to DCF valuation for stock investing

Learn how to determine fair value like the best investors in the world.

Below Future Cash Flow Value: ACLX ($114.72) is trading below our estimate of future cash flow value ($486.26)

Significantly Below Future Cash Flow Value: ACLX is trading below future cash flow value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for ACLX?

Key metric: As ACLX barely has revenue we use its Price-To-Book Ratio for relative valuation analysis.

The above table shows the Price to Book ratio for ACLX. This is calculated by dividing ACLX's market cap by their current book value.
What is ACLX's PB Ratio?
PB Ratio16.7x
BookUS$402.35m
Market CapUS$6.73b

Price to Book Ratio vs Peers

How does ACLX's PB Ratio compare to its peers?

The above table shows the PB ratio for ACLX vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PBEstimated GrowthMarket Cap
Peer Average41.9x
ALKS Alkermes
3.1x31.23%US$5.8b
HALO Halozyme Therapeutics
153.1x11.71%US$7.6b
APGE Apogee Therapeutics
6.9x0.32%US$6.2b
KYMR Kymera Therapeutics
4.4x-3.46%US$7.0b
ACLX Arcellx
16.7x64.14%US$6.7b

Price-To-Book vs Peers: ACLX is good value based on its Price-To-Book Ratio (16.7x) compared to the peer average (41.9x).

Historical Price to Book Ratio

Historical Price to Book Ratio compares a stock's price to the book value of it's equity over time. Higher ratios indicate that investors are willing to pay more for the stock.

Fetching historical data

Price to Book Ratio vs Industry

How does ACLX's PB Ratio compare vs other companies in the US Biotechs Industry?

56 CompaniesPrice / BookEstimated GrowthMarket Cap
ENLV Enlivex
0.1x-73.97%US$225.99m
CNTN Canton Strategic Holdings
0.5xn/aUS$184.70m
ACET Adicet Bio
0.5x26.03%US$75.14m
CYPH Cypherpunk Technologies
0.5xn/aUS$68.69m
ACLX 16.7xIndustry Avg. 2.2xNo. of Companies84PB0246810+
56 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Book vs Industry: ACLX is expensive based on its Price-To-Book Ratio (16.7x) compared to the US Biotechs industry average (2.2x).

Price to Book Ratio vs Fair Ratio

What is ACLX's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

ACLX PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio16.7x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate ACLX's Price-To-Book Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst ACLX forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$114.72
US$111.07
-3.18%
9.71%US$120.00US$82.00n/a14
Mar ’27US$113.79
US$111.07
-2.39%
9.71%US$120.00US$82.00n/a14
Feb ’27US$68.31
US$112.35
+64.48%
9.86%US$134.00US$88.00n/a17
Jan ’27US$65.20
US$112.35
+72.32%
9.86%US$134.00US$88.00n/a17
Dec ’26US$70.28
US$113.13
+60.96%
9.69%US$134.00US$88.00n/a16
Nov ’26US$90.25
US$112.82
+25.01%
9.02%US$134.00US$88.00n/a17
Oct ’26US$82.03
US$113.07
+37.84%
7.03%US$134.00US$100.00n/a15
Sep ’26US$69.39
US$113.07
+62.94%
7.03%US$134.00US$100.00n/a15
Aug ’26US$71.14
US$113.80
+59.97%
8.16%US$134.00US$100.00n/a15
Jul ’26US$64.69
US$111.13
+71.79%
8.21%US$134.00US$93.00n/a15
Jun ’26US$62.06
US$111.53
+79.72%
8.65%US$134.00US$93.00n/a15
May ’26US$65.53
US$115.40
+76.10%
7.68%US$134.00US$104.00n/a15
Apr ’26US$60.70
US$115.40
+90.12%
7.68%US$134.00US$104.00US$114.7515
Mar ’26US$64.82
US$116.13
+79.15%
7.10%US$134.00US$104.00US$113.7916
Feb ’26US$68.13
US$116.38
+70.81%
7.18%US$134.00US$104.00US$68.3116
Jan ’26US$76.69
US$116.38
+51.75%
7.18%US$134.00US$104.00US$65.2016
Dec ’25US$88.07
US$114.44
+29.94%
9.07%US$134.00US$95.00US$70.2816
Nov ’25US$86.17
US$95.56
+10.90%
16.63%US$122.00US$73.00US$90.2516
Oct ’25US$81.44
US$83.71
+2.79%
9.03%US$106.00US$73.00US$82.0314
Sep ’25US$68.74
US$79.87
+16.19%
5.80%US$87.00US$70.00US$69.3915
Aug ’25US$58.65
US$79.93
+36.29%
5.75%US$87.00US$70.00US$71.1415
Jul ’25US$53.60
US$79.93
+49.13%
5.75%US$87.00US$70.00US$64.6915
Jun ’25US$52.00
US$79.93
+53.72%
5.75%US$87.00US$70.00US$62.0615
May ’25US$52.18
US$80.31
+53.91%
4.82%US$87.00US$73.00US$65.5313
Apr ’25US$66.98
US$80.31
+19.90%
4.82%US$87.00US$73.00US$60.7013
US$111.07
Fair Value
3.3% overvalued intrinsic discount
14
Number of Analysts

Analyst Forecast: Target price is lower than the current share price.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/04/06 15:44
End of Day Share Price 2026/04/06 00:00
Earnings2025/12/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Arcellx, Inc. is covered by 25 analysts. 14 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Jack AllenBaird
Jason Matthew GerberryBofA Global Research
John NewmanCanaccord Genuity